Aetna's Q2 2026 medical benefit ratio fell 250 basis points to 87.4% from 89.9%, and CVS Health's chief financial officer put a number on how much of that came from reserving rather than current claims: roughly $500 million, or 140 basis points, from favorable prior-year development and related items in the quarter alone (CVS Health, Q2 2026 earnings call, August 2026).

That single disclosure reframes a result the trade press is calling a turnaround. CVS Health's net income nearly tripled to $2.995 billion in the quarter, up from $1.013 billion a year earlier, and the company raised full-year adjusted EPS guidance by $0.60 to a range of $7.90 to $8.10 (CVS Health earnings release, August 2026). None of that is in dispute. What the 250-basis-point MBR improvement obscures is how much of it traces to two reserving mechanics, a released prior-year cushion and the absence of a deficiency charge booked a year ago, rather than to a genuine improvement in how the current book of Medicare Advantage and commercial business is running.

The $500 Million Behind the Quarter, and the $1.2 Billion Behind the Half

CFO Brian Newman was explicit on the earnings call about the composition of the improvement: "medical benefit ratio was 87.4%, both of which improved meaningfully from the prior year quarter," and separately, that favorable prior-year development and related items "contributed approximately $500 million or 140 basis points to our MBR in the quarter" (CVS Health Q2 2026 earnings call transcript, August 2026). Zoom out to the six-month window and the reserving contribution is larger still: the company's own health care costs payable rollforward shows prior-years' estimates developing favorably by $1.2 billion during the six months ended June 30, 2026 (CVS Health Form 10-Q, Q2 2026, SEC EDGAR). A 140-basis-point quarterly boost from development and related items is a meaningful chunk of a 250-basis-point year-over-year improvement, roughly 56% of it, before any accounting for the second reserving item working in Aetna's favor this quarter.

That second item is the year-ago comparison itself. CVS Health recorded a $471 million premium deficiency reserve within its Group Medicare Advantage product line in the second quarter of 2025, tied to anticipated losses for the remainder of that coverage year, and the company confirmed it established no other premium deficiency reserves during the three or six months ended June 30, 2026 (CVS Health Form 10-Q, Q2 2026, SEC EDGAR). A premium deficiency reserve exists specifically because an actuary has concluded that expected future losses on in-force contracts will exceed the premium remaining to be earned on them, so booking one is a forward-looking loss recognition, not a claims-experience read. Lapping it a year later, with no replacement charge, mechanically lowers the reported MBR even if nothing about current medical cost trend changed at all. Between the $500 million of quarterly favorable development and the absence of a $471 million deficiency charge, the two reserving items alone account for a meaningful share of the year-over-year MBR swing, leaving a comparatively modest residual attributable to genuine current-period claims performance.

ItemQ2 2025Q2 2026Effect on Q2 2026 MBR
Reported Aetna/HCB MBR89.9%87.4%Improved 250 bps
Group MA premium deficiency reserve$471M bookedNone bookedLapped charge lowers MBR
Favorable prior-year development, quarterNot separately quantified~$500M / 140 bpsLowers MBR
Six-month favorable prior-year developmentn/a$1.2BLowers cumulative MBR

What a Premium Deficiency Reserve Reversal Actually Signals

A premium deficiency reserve is one of the more consequential loss-recognition tools available to a health actuary, precisely because it is prospective. Under statutory and GAAP guidance, a carrier books a PDR when the present value of expected future claims and expenses on existing contracts exceeds the present value of remaining premium, net of any deferred acquisition costs, effectively pulling forward the recognition of a loss the block has not yet incurred. Aetna's $471 million Group Medicare Advantage PDR in Q2 2025 said, in actuarial terms, that management expected that specific in-force book to lose money for the balance of the 2025 coverage year severely enough to warrant an immediate charge rather than waiting for the losses to emerge claim by claim.

The reserve's absence in 2026 is consistent with two different stories, and the earnings materials support the more favorable one: Aetna repriced the Group Medicare Advantage book hard enough into the 2026 bid year that the projected loss no longer exists. Aetna President Steve Nelson credited a "strong medical cost management approach" for producing "really strong momentum in this business for 2026" (CVS Health Q2 2026 earnings call transcript, August 2026), and the segment's improved underlying performance in Medicare, cited independently by Forbes' reporting on the quarter, points the same direction. But a lapped PDR is a comparison-period effect, not a repeatable one: it cannot lower next year's MBR again unless Aetna books a new deficiency charge in a future period and then reverses that one too. Treating the year-over-year MBR improvement as 250 basis points of durable margin gain, rather than partly a base-period artifact, overstates the run-rate benefit an analyst should carry into a 2027 model.

Days Claims Payable: The Cushion Is Thinning, Not Just the Ratio

The clearest independent read on reserve adequacy sits outside the MBR entirely, in the balance-sheet metric days claims payable, which measures how many days of average claims expense the health care costs payable liability could cover if claims stopped entirely. Aetna's days claims payable fell to 41.7 at June 30, 2026 from 42.9 at March 31, 2026, a sequential decline of 1.2 days (CVS Health Form 10-Q, Q2 2026, SEC EDGAR). Days claims payable moves for benign reasons, faster claims adjudication cycles, seasonal membership mix shifts, and it is not itself proof of under-reserving. But a shrinking cushion arriving in the same quarter as $500 million of favorable development being released is the combination a reserving actuary should read together rather than separately: the balance sheet reserve is both being drawn down through releases and covering fewer days of prospective claims than it was three months earlier.

The mechanical relationship matters for how much confidence to place in the release pattern continuing. Health care costs payable is built from actuarially estimated completion factors applied to claims received to date, and every dollar released as favorable development in a given quarter is, by construction, a dollar that will not be available to release in a subsequent quarter unless a fresh round of conservatism gets built into new accident-period picks. A carrier can sustain a run of favorable development for several quarters if initial reserves were set with genuine margin during a period of elevated uncertainty, which is exactly what happened across the industry during the 2023 to 2024 Medicare Advantage utilization spike. Whether Aetna's remaining cushion, evidenced by the declining days-payable figure, can support the same $500 million-plus pace of quarterly releases into 2027 is a separate question from whether the current quarter's MBR looks good, and the two should not be conflated in a forward model.

Membership: Medicare Advantage Steady, ACA Exchange Gone

Aetna's Medicare Advantage membership stood at 4.202 million at June 30, 2026, essentially flat against 4.240 million a year earlier and up modestly from 4.175 million at the end of the first quarter (CVS Health Form 10-Q, Q2 2026, SEC EDGAR). Flat-to-slightly-declining MA membership after two years of aggressive star-rating-driven benefit cuts and network narrowing is itself a data point: Aetna appears to have prioritized margin recovery over enrollment growth through the 2026 bid cycle, a trade a health actuary would expect to see given the PDR the company was carrying a year earlier.

Total medical membership fell by roughly 700,000 members year over year, and Newman attributed the decline "primarily" to the company's "previously discussed exit from the individual exchange business" (CVS Health Q2 2026 earnings call transcript, August 2026). Exiting the ACA individual exchange market is a favorable move for reported MBR trend independent of anything happening in the retained book: exchange risk pools carry the highest morbidity uncertainty of any commercial line, subject to open enrollment adverse selection and a risk-adjustment transfer mechanism that can swing margins by hundreds of basis points depending on how a carrier's relative risk score compares with the statewide average. Removing that block from the denominator changes the blended MBR's composition even if nothing about the remaining Medicare and commercial business improved at all, a mix effect distinct from, and additive to, the reserving items already discussed.

Setting Up the 2027 Medicare Advantage Bid Cycle

The reserving mechanics land directly on the numbers Aetna is using to build 2027 Medicare Advantage bids, submitted to CMS each June for the following plan year. Nelson told analysts the company is "taking that same focus to return the business to target margins, and the same discipline," and that Aetna "assumed a continuation of the elevated trend" as it built its 2027 bids (CVS Health Q2 2026 earnings call transcript, August 2026). That is a notably conservative posture for a carrier reporting 250 basis points of MBR improvement, and it is the tell that Aetna's own actuaries are not reading the Q2 print as proof that medical cost trend has genuinely decelerated. A bid built on continued elevated trend assumptions, layered onto a book whose reported margin recovery partly reflects one-time reserving items rather than repriced unit costs, is the more defensible actuarial posture: CMS bid pricing locks in a full plan year of risk, and a carrier that under-prices 2027 off a flattered 2026 base repeats the exact mistake that produced the 2025 deficiency reserve in the first place.

CVS Health's own guidance history over the past two years supports reading the reserving items as a deliberate correction rather than a cyclical trend reversal. The company has now booked two consecutive years of significant Medicare Advantage reserve strengthening, the 2025 PDR followed by a year of favorable development against it, a pattern consistent with a carrier that overshot conservative on 2025 pricing, took the deficiency charge when it became clear the book would lose money, then found the charge was larger than the ultimate loss turned out to be. That is not evidence of bad-faith reserving; it is evidence of a genuinely uncertain pricing environment where CMS risk-model changes, star-rating benefit design, and utilization trend all shifted meaningfully within a single bid cycle. It does mean an analyst extrapolating the 87.4% MBR forward into 2027 bid economics is assuming a repeat performance of a reserving cycle that, by its own mechanics, cannot repeat in the same form twice.

Reading Aetna Against UnitedHealth and Elevance

Aetna's reserving-driven improvement is not happening in isolation. actuary.info's analysis of the Q2 2026 UnitedHealth and Elevance results found UnitedHealthcare's medical benefit ratio falling 270 basis points to 86.7%, helped in part by favorable prior-year development and a milder respiratory season, while Elevance's ratio moved the opposite direction, up 80 basis points to 89.7%, on Medicaid margin compression that has proven more persistent. That divergence read applies to Aetna's print as well: a managed-care sector reporting improved headline ratios is not uniformly improving on a current-accident-year basis, and the carriers whose MBR gains lean most heavily on prior-year releases and lapped one-time charges, Aetna and UnitedHealth among them, are the ones whose 2027 guidance deserves the most scrutiny for how much of the 2026 base rate is durable.

Molina's Medicaid book offers the counterpoint from the same earnings season. actuary.info's coverage of Molina's Q2 2026 result showed a Medicaid medical cost ratio of 92.7%, up from 91.3%, with CEO Joseph Zubretsky calling 2026 the trough year for Medicaid margins even as redetermination-driven acuity mix pushed the ratio the wrong way. Medicaid carriers are seeing the acuity consequences of eligibility redeterminations flow into current claims in real time, while Medicare Advantage carriers like Aetna are working through a slower-moving reserving cycle tied to CMS risk-model transitions. Both dynamics are reserving stories at their core, but they sit on opposite sides of the release-versus-strengthen line this quarter, and conflating "managed care margins are recovering" across both lines misses the mechanism doing the work in each.

What the Q2 Print Implies for a 2027 Reserving Model

A reserving actuary building loss-development triangles off Aetna's reported results has three distinct signals to separate rather than blend into a single trend line. The first is the $1.2 billion of six-month favorable development, a genuine but non-repeating recognition of conservatism built into 2024 and 2025 accident-period picks now proving redundant. The second is the lapped $471 million PDR, a base-period comparison effect that flatters the year-over-year delta without saying anything about current unit costs. The third, and the one CMS bid actuaries appear to be weighting most heavily given Nelson's own comments about continued elevated trend, is that neither of the first two signals should be read as evidence that Medicare Advantage medical cost trend has decelerated enough to loosen 2027 pricing discipline.

Days claims payable falling to 41.7 from 42.9 in a single quarter, alongside the largest reserve release of the year, is the detail worth tracking into the third-quarter print. If the ratio stabilizes or rebounds as the redundant 2024 and 2025 accident-year cushion finishes working through the system, that is consistent with a carrier that repriced correctly and is now running a leaner but adequate reserve position. If it keeps declining while releases continue at a similar pace, that combination would suggest the reserve cushion is being drawn down faster than fresh accident-year conservatism is replacing it, a pattern that would matter considerably more for 2027 bid adequacy than the 250-basis-point MBR headline currently receiving the coverage.

Further Reading

Sources